INEP medical s.r.o. — Clinical Trial Site

37 Registered trials

15 Currently recruiting

Organisation

INEP medical s.r.o.

Location

Prague, Czechia

Identifier

ORG-100043271

Address

Soubezna II 664 29, 158 00, Czechia

Departments

203003: INEP medical s.r.o.
Chronic pain
INEP MedicaL s.r.o.
Institut neuropsychiatrické péče
Institute of Neuropsychiatric Care
n/a
NA
Neurologické oddělení, klinická hodnocení
Neurology
Neurology Department
Oddeleni psychiatrie
Private practice
psychiatrická ambulance
Psychiatry

Clinical trials at this site (37)

Search interface

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 Major Depressive Disorder 5 2026-02-26
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, d… Recruiting

2024-516852-17-00 Tardive dyskinesia 4 2023-11-13
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Agitation Associated with Alzheimer’s Disease 5 2025-11-28
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-11-26
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 Major Depressive Disorder 5 2025-09-19
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting

2023-507351-29-00 Alzheimer's Disease Psychosis 5 2024-12-03
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen… Ended

2024-513572-17-00 Generalized Anxiety Disorder (GAD) 5 2025-08-20
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Alzheimer Disease psychosis 4 2024-07-02
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18